Casdin Capital »

Tempus Ai shares owned by Casdin Capital

Quarter-by-quarter ownership of Tempus Ai (TEM) shares owned by Casdin Capital from 13F filings

Historical chart of Casdin Capital investment in Tempus Ai

Tip: Access up to 7 years of quarterly data

All positions including Tempus Ai held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tempus Ai by Casdin Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $24M 294k 80.71

More positions owned by Casdin Capital

Genedx Holdings Corp Com Cl A (WGS)
Biolife Solutions Com New (BLFS)
Revolution Medicines (RVMD)
D Fluidigm Corp Del (LAB)
Avidity Biosciences Ord (RNA)
Relay Therapeutics (RLAY)
Illumina (ILMN)
Structure Therapeutics Sponsored Ads (GPCR)
Beam Therapeutics (BEAM)
Alnylam Pharmaceuticals (ALNY)
Tempus Ai Cl A (TEM)
Neurogene (NGNE)
Maze Therapeatics (MAZE)
Prime Medicine (PRME)
Silverback Therapeutics (SPRY)

View all positions for Casdin Capital

Top funds holding Tempus Ai

Susquehanna International
Baillie Gifford & Co
Vanguard Group
ARK Investment Management
BlackRock
Jane Street
D. E. Shaw & Co
Softbank Group Corp
Jpmorgan Chase & Co
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
UBS Group
Morgan Stanley
Citadel Advisors
Geode Capital Management

View all funds holding Tempus Ai